Table 7.
Results for gabapentin therapy during follow-up of 41 patients
| Test (range) | 135th day | 165th day | 205th day |
| Hamilton rating scalec(0-66) | 9.7 ± 0.4 | 9.7 ± 0.5 | 10.0 ± 0.7 |
| (-9.8 ± 0.2; < 0.01) | (-9.8 ± 0.3; < 0.01) | (-9.9 ± 1.2; < 0.01) | |
| PSQI (0-5) | 2.7 ± 0.7 | 2.9 ± 0.3 | 3.0 ± 0.5 |
| (+ 0.7 ± 0.2; NS) | (+0.5 ± 0.2; NS) | (+0.6 ± 0.3; NS) | |
| ESS (0-24) | 9 9 ± 0.7 | 9. 5 ± 0.4 | 12 .7 ± 1.1 |
| (-0.7 ± 1.0; NS) | (-0.5 ± 0.1; NS) | (-3.3 ± 0.1; < 0.05) | |
| IRSL (0-40) | 0-10 (mild) = 21 | 18 | 17 |
| 11-20 (moderate) = 14 | 19 | 22 | |
| 21-30 (severe) = 6 | 4 | 2 | |
| 31-40 (very severe) = 0 | 0 | 0 |
Within-group analysis was done by comparing results at each day’s visit vs the 45th day results. ESS: Excessive diurnal sleepiness; IRLS: International RLS severity scoring system; NS: Nonsignificant; PSQI: Depression, sleep quality assessment.